ERCP术后胰腺炎的危险因素及预防方法

摘要/Abstract

摘要：

内镜逆行胰胆管造影术(endoscopic retrograde cholangio-pancreatography, ERCP)是胆胰疾病诊断的主要操作技术之一。ERCP术后胰腺炎(post-ERCP pancreatitis, PEP)是ERCP术后最常见的并发症，延长病人的住院时间，重症胰腺炎甚至危及生命。了解PEP的危险因素对于预防PEP的发生至关重要。目前常见的PEP危险因素包括病人自身的和ERCP操作相关的。根据这些危险因素，予以相关的术前、术中、术后干预可有效降低PEP的发生率。本文总结阐述目前常见的PEP危险因素及预防方法，供广大临床工作者参考。

关键词:内镜逆行胰胆管造影术,ERCP术后急性胰腺炎,危险因素,预防

Abstract:

Endoscopic retrograde cholangio-pancreatography (ERCP) is one of the primary procedural techniques used for diagnosing biliary and pancreatic diseases. Post-ERCP pancreatitis (PEP) is the most common complication of ERCP, which resulted in prolonged hospitalization and potential risk of patients' lives, especially in severe cases. Understanding the risk factors associated with PEP is of paramount importance for its prevention. Currently, recognized risk factors for PEP encompass both patient-related factors and ERCP procedure-related factors. By considering these risk factors, implementing appropriate preoperative, intraoperative, and postoperative interventions could effectively reduce the incidence of PEP. In this article, we concisely summarized the common risk factors and preventive methods for PEP, offering valuable insights for healthcare professionals in clinical practice.

Key words:Endoscopic retrograde cholangio-pancreatography,Post-ERCP pancreatitis,Risk factor,Prevention

中图分类号:

R576

聂海行, 王帆, 王红玲, 赵秋. ERCP术后胰腺炎的危险因素及预防方法[J]. 外科理论与实践, 2023, 28(04): 310-315.

NIE Haihang, WANG Fan, WANG Hongling, ZHAO Qiu. Risk factors and prevention methods for post-ERCP pancreatitis[J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 310-315.

参考文献47

[1]	DUMONCEAU J M, ANDRIULLI A, ELMUNZER B J, et al. Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) guideline - updated June 2014[J]. Endoscopy, 2014, 46(9):799-815. doi:10.1055/s-00000012 URL
[2]	BUXBAUM J L, FREEMAN M, AMATEAU S K, et al. American Society for Gastrointestinal Endoscopy guideline on post-ERCP pancreatitis prevention strategies: methodology and review of evidence[J]. Gastrointest Endosc, 2023, 97(2):163-183. doi:10.1016/j.gie.2022.09.011 URL
[3]	OBEIDAT A E, MAHFOUZ R, MONTI G, et al. Post-endoscopic retrograde cholangiopancreatography pancreatitis: what we already know[J]. Cureus, 2022, 14(1):e21773.
[4]	JAMRY A. Risk factors of pancreatitis after endoscopic sphincterotomy. Review of literature and practical remarks based on approximately 10,000 ERCPs[J]. Pol Przegl Chir, 2017, 89(5):29-33. doi:10.5604/01.3001.0010.5409pmid:29154236
[5]	FREEMAN M L, DISARIO J A, NELSON D B, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study[J]. Gastrointest Endosc, 2001, 54(4):425-434. doi:10.1067/mge.2001.117550pmid:11577302
[6]	MADÁCSY L, KURUCSAI G, FEJES R, et al. Prophylactic pancreas stenting followed by needle-knife fistulotomy in patients with sphincter of Oddi dysfunction and difficult cannulation: new method to prevent post-ERCP pancreatitis[J]. Dig Endosc, 2009, 21(1):8-13. doi:10.1111/j.1443-1661.2008.00819.xpmid:19691794
[7]	陈文华, 林军, 王剑屏, 等. ERCP术后胰腺炎的危险因素及预防措施[J]. 国际消化病杂志, 2018, 38(2):79-83.
	CHEN W H, LIN J, WANG J P, et al. Risk factors and preventive measures of post-ERCP pancreatitis[J]. Int J Dig Dis, 2018, 38(2):79-83.
[8]	李雄, 田宏伟, 龚世怡, 等. ERCP术后胰腺炎危险因素预防的研究进展[J]. 宁夏医科大学学报, 2023, 45(3):319-324.
	LI X, TIAN H W, GONG S Y, et al. Advances in the prevention of risk factors for pancreatitis after ERCP[J]. J Ningxia Med Univ, 2023, 45(3):319-324.
[9]	PEKGÖZ M. Post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review for prevention and treatment[J]. World J Gastroenterol, 2019, 25(29):4019-4042. doi:10.3748/wjg.v25.i29.4019 URL
[10]	MARTÍNEZ-MONEO E, CÁRDENAS-JAÉN K, FERNÁNDEZ-LASO A B, et al. Statin consumption and risk of post-endoscopic retrograde cholangiopancreatography pancreatitis[J]. Pancreatology, 2020, 20(5):801-805. doi:10.1016/j.pan.2020.05.002 URL
[11]	SAITO H, KADONO Y, SHONO T, et al. Increased post-endoscopic retrograde cholangiopancreatography pancrea-titis for choledocholithiasis without acute cholangitis[J]. J Gastroenterol Hepatol, 2022, 37(2):327-334. doi:10.1111/jgh.v37.2 URL
[12]	CORWIN M T, LAMBA R, MCGAHAN J P. Functional MR cholangiography of the cystic duct and sphincter of Oddi using gadoxetate disodium: is a 30-minute delay long enough?[J]. J Magn Reson Imaging, 2013, 37(4):993-998. doi:10.1002/jmri.23816pmid:23001618
[13]	KUNWALD P, DREWES A M, KJAER D, et al. A new distensibility technique to measure sphincter of Oddi function[J]. Neurogastroenterol Motil, 2010, 22(9):978-983, e253. doi:10.1111/nmo.2010.22.issue-9 URL
[14]	YAN X, ZHENG W, ZHANG Y, et al. Endoclip papillaplasty restores sphincter of Oddi function: pilot study[J]. Dig Endosc, 2021, 33(6):962-969. doi:10.1111/den.13887pmid:33145797
[15]	MENG Q Q, ZHAO S B, WANG Z J, et al. Incidence and risk factors for post-ERCP pancreatitis in pancreas divisum patients without chronic pancreatitis[J]. Scand J Gastroenterol, 2020, 55(6):732-736. doi:10.1080/00365521.2020.1774922 URL
[16]	TESTONI P A, VAILATI C, GIUSSANI A, et al. ERCP-induced and non-ERCP-induced acute pancreatitis: two distinct clinical entities with different outcomes in mild and severe form?[J]. Dig Liver Dis, 2010, 42(8):567-570. doi:10.1016/j.dld.2009.10.008 URL
[17]	PARK C H, PARK S W, YANG M J, et al. Pre- and post-procedure risk prediction models for post-endoscopic retrograde cholangiopancreatography pancreatitis[J]. Surg Endosc, 2022, 36(3):2052-2061. doi:10.1007/s00464-021-08491-1
[18]	TESTONI P A, MARIANI A, GIUSSANI A, et al. Risk factors for post-ERCP pancreatitis in high- and low-volume centers and among expert and non-expert operators: a prospective multicenter study[J]. Am J Gastroenterol, 2010, 105(8):1753-1761. doi:10.1038/ajg.2010.136pmid:20372116
[19]	FACCIORUSSO A, RAMAI D, GKOLFAKIS P, et al. Comparative efficacy of different methods for difficult biliary cannulation in ERCP: systematic review and network meta-analysis[J]. Gastrointest Endosc, 2022, 95(1):60-71.e12. doi:10.1016/j.gie.2021.09.010 URL
[20]	DUMONCEAU J M, ANDRIULLI A, DEVIERE J, et al. European Society of Gastrointestinal Endoscopy (ESGE) guideline: prophylaxis of post-ERCP pancreatitis[J]. Endoscopy, 2010, 42(6):503-515. doi:10.1055/s-0029-1244208pmid:20506068
[21]	ERGIN E, ORUÇ N, ERSÖZ G, et al. Prognosis and risk factors of ERCP pancreatitis in elderly[J]. Sci Rep, 2021, 11(1):15930. doi:10.1038/s41598-021-95484-8pmid:34354184
[22]	KOHLI K, SAMANT H, KHAN K, et al. Risk stratification in post-ERCP pancreatitis: how do procedures, patient characteristics and clinical indicators influence outcomes?[J]. Pathophysiology, 2021, 28(1):76-85. doi:10.3390/pathophysiology28010007 URL
[23]	YANG H, YANG Z, HONG J. Post-ERCP pancreatitis occurs more frequently in self-expandable metallic stents than multiple plastic stents on benign biliary strictures: a meta-analysis[J]. Ann Med, 2022, 54(1):2439-2449. doi:10.1080/07853890.2022.2105395pmid:36799364
[24]	中华医学会消化内镜学分会, 中国医师协会胰腺病专业委员会. 内镜下逆行胰胆管造影术后胰腺炎药物预防专家共识意见(2015年,上海)[J]. 中华消化内镜杂志, 2015, 32(12):794-799.
	Chinese Society of Digestive Endoscopy, Chinese Medical Association Pancreatic Disease Committee of Chinese Medical Doctor Association. Expert consensus statement on the pharmacologic prophylaxis of post ERCP pancrea-titis in China (2015, Shanghai)[J]. J Clin Hepatol, 2015, 32(12):794-799.
[25]	NAWAZ M H, SARWAR S, NADEEM M A. Post-ERCP pancreatitis: risk factors and role of NSAIDs in primary prophylaxis[J]. Pak J Med Sci, 2020, 36(3):426-431. doi:10.12669/pjms.36.3.1804pmid:32292447
[26]	AKSHINTALA V S, SPERNA WEILAND C J, BHULLAR F A, et al. Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and network meta-analysis[J]. Lancet Gastroenterol Hepatol, 2021, 6(9):733-742. doi:10.1016/S2468-1253(21)00170-9 URL
[27]	GERACI G, PALUMBO V D, D'ORAZIO B, et al. Rectal diclofenac administration for prevention of post-endoscopic retrograde cholangio-pancreatography (ERCP) acute pancreatitis. Randomized prospective study[J]. Clin Ter, 2019, 170(5):e332-e336.
[28]	MAKHZANGY H E, SAMY S, SHEHATA M, et al. Combined rectal indomethacin and intravenous saline hydration in post-ERCP pancreatitis prophylaxis[J]. Arab J Gastroenterol, 2022, 23(2):95-101. doi:10.1016/j.ajg.2022.01.004pmid:35153177
[29]	KATO K, SHIBA M, KAKIYA Y, et al. Celecoxib oral administration for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized prospective trial[J]. Pancreas, 2017, 46(7):880-886. doi:10.1097/MPA.0000000000000852 URL
[30]	ISHIWATARI H, URATA T, YASUDA I, et al. No benefit of oral diclofenac on post-endoscopic retrograde cholangiopancreatography pancreatitis[J]. Dig Dis Sci, 2016, 61(11):3292-3301. doi:10.1007/s10620-016-4251-x URL
[31]	MÁRTA K, GEDE N, SZAKÁCS Z, et al. Combined use of indomethacin and hydration is the best conservative approach for post-ERCP pancreatitis prevention: a network meta-analysis[J]. Pancreatology, 2021, 21(7):1247-1255. doi:10.1016/j.pan.2021.07.005pmid:34353727
[32]	RADADIYA D, BRAHMBHATT B, REDDY C, et al. Efficacy of combining aggressive hydration with rectal indomethacin in preventing post-ERCP pancreatitis: a systematic review and network meta-analysis[J]. J Clin Gastroenterol, 2022, 56(3):e239-e249. doi:10.1097/MCG.0000000000001523 URL
[33]	MAKHZANGY H E, SAMY S, SHEHATA M, et al. Combined rectal indomethacin and intravenous saline hydration in post-ERCP pancreatitis prophylaxis[J]. Arab J Gastroenterol, 2022, 23(2):95-101. doi:10.1016/j.ajg.2022.01.004pmid:35153177
[34]	HAJALIKHANI M, EMAMI M H, KHODADOOSTAN M, et al. Combination of diclofenac and aggressive hydration for the prevention of post-ERCP pancreatitis[J]. Gastroenterol Hepatol Bed Bench, 2018, 11(4):319-324.
[35]	QIN X, LEI W S, XING Z X, et al. Prophylactic effect of somatostatin in preventing post-ERCP pancreatitis: an updated meta-analysis[J]. Saudi J Gastroenterol, 2015, 21(6):372-378. doi:10.4103/1319-3767.167187pmid:26655132
[36]	WANG G, XIAO G, XU L, et al. Effect of somatostatin on prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis and hyperamylasemia: a systematic review and meta-analysis[J]. Pancreatology, 2018, 18(4):370-378. doi:S1424-3903(18)30040-1pmid:29550097
[37]	NOROUZI A, GHASEM POORI E, KAABE S, et al. Effect of adding intravenous somatostatin to rectal indomethacin on post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis in high-risk patients: a double-blind randomized placebo-controlled clinical trial[J]. J Clin Gastroenterol, 2023, 57(2):204-210. doi:10.1097/MCG.0000000000001563 URL
[38]	BHATT H. Post-endoscopic retrograde cholangiopancreatography pancreatitis: an updated review of current preventive strategies[J]. Clin Exp Gastroenterol, 2021, 14:27-32. doi:10.2147/CEG.S276361pmid:33564256
[39]	SHI Q Q, HUANG G X, LI W, et al. Rectal nonsteroidal anti-inflammatory drugs, glyceryl trinitrate, or combinations for prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: a network meta-analysis[J]. World J Clin Cases, 2022, 10(22):7859-7871. doi:10.12998/wjcc.v10.i22.7859 URL
[40]	WANG Y, XU B, ZHANG W, et al. Prophylactic effect of rectal indomethacin plus nitroglycerin administration for preventing pancreatitis after endoscopic retrograde cholangiopancreatography in female patients[J]. Ann Palliat Med, 2020, 9(6):4029-4037. doi:10.21037/apm-20-1963pmid:33302662
[41]	KOHLI K, SAMANT H, KHAN K, et al. Risk stratification in post-ERCP pancreatitis: how do procedures, patient characteristics and clinical indicators influence outcomes?[J]. Pathophysiology, 2021, 28(1):76-85. doi:10.3390/pathophysiology28010007 URL
[42]	MAZAKI T, MADO K, MASUDA H, et al. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: an updated meta-analysis[J]. J Gastroenterol, 2014, 49(2):343-355. doi:10.1007/s00535-013-0806-1pmid:23612857
[43]	AFGHANI E, AKSHINTALA V S, KHASHAB M A, et al. 3-Fr pancreatic stents for the prevention of post-ERCP pancreatitis in high-risk patients: a systematic review and network meta-analysis[J]. Endoscopy, 2014, 46(7):573-580. doi:10.1055/s-00000012 URL
[44]	CHA S W, LEUNG W D, LEHMAN G A, et al. Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy-associated pancreatitis? A randomized, prospective study[J]. Gastrointest Endosc, 2013, 77(2):209-216. doi:10.1016/j.gie.2012.08.022 URL
[45]	CHOKSI N S, FOGEL E L, COTE G A, et al. The risk of post-ERCP pancreatitis and the protective effect of rectal indomethacin in cases of attempted but unsuccessful prophylactic pancreatic stent placement[J]. Gastrointest Endosc, 2015, 81(1):150-155. doi:10.1016/j.gie.2014.07.033pmid:25527053
[46]	TSE F, YUAN Y, MOAYYEDI P, et al. Guide wire-assisted cannulation for the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis[J]. Endoscopy, 2013, 45(8):605-618. doi:10.1055/s-0032-1326640pmid:23807804
[47]	TSE F, YUAN Y, MOAYYEDI P, et al. Double-guidewire technique in difficult biliary cannulation for the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis[J]. Endoscopy, 2017, 49(1):15-26. doi:10.1055/s-0042-119035pmid:27997966